Pyxis Oncology, Inc.

NasdaqGS:PYXS Stock Report

Market Cap: US$107.7m

Pyxis Oncology Past Earnings Performance

Past criteria checks 0/6

Pyxis Oncology's earnings have been declining at an average annual rate of -3.9%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 59.2% per year.

Key information

-3.88%

Earnings growth rate

75.82%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate59.23%
Return on equity-261.40%
Net Margin-589.80%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Sep 12

Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

Summary PYXS is developing micvotabart pelidotin for head and neck squamous cell carcinoma, with key clinical readouts expected in H2'25 and H1'26. While micvotabart pelidotin has shown early efficacy and tolerability, limited patient data and competition raise concerns. PYXS has cash runway into H2'26 but faces risk from potential clinical disappointments, competitor updates, and possible dilutive fundraising. Read the full article on Seeking Alpha
Analysis Article • Jun 19

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 07

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Summary Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company’s valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types. Investors should consider PYXS's financial runway, speculative nature, and potential for significant stock appreciation if future trial results are favorable. Despite setbacks, PYXS's valuation appears deeply oversold, presenting a speculative "Buy" opportunity due to its robust pipeline and potential revenue from licensing. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Moment Of Truth Approaches For Pyxis Oncology

Summary Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024. PYXS estimates its current cash will last until H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jun 10

Pyxis Oncology: Promising Research Amid Cash Constraints

Summary Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple solid tumor types, with preliminary data expected in 2024. Pyxis recently announced a workforce reduction and sold the royalties and commercialization rights of Beovu to extend its cash runway. Despite innovative technology, PYXS faces financial constraints and early-stage development risks. A neutral stance on PYXS is prudent due to speculative IP and potential shareholder dilution. Read the full article on Seeking Alpha
Seeking Alpha • Mar 28

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds with a private placement in February 2024 and is cashed into H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Summary Pyxis Oncology is a biotech company focused on developing immunotherapies for cancer treatment. Their most advanced pipeline project is sotigalimab, a CD40 agonist, which has shown promising results in melanoma and liposarcoma. The company has enough funds to continue operating for 5-6 quarters, but future funding may require dilutive financing. Read the full article on Seeking Alpha
Analysis Article • Feb 18

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Sep 01

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 15

Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06

Pyxis Oncology press release (NASDAQ:PYXS): Q2 GAAP EPS of -$0.79 beats by $0.06. Pyxis Oncology had cash and cash equivalents of $223 million as of June 30, 2022, and approximately $207 million (preliminary, unaudited) as of August 15, 2022, which is expected to fund operations through the second half of 2024.
Analysis Article • Apr 13

We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Revenue & Expenses Breakdown

How Pyxis Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:PYXS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2614-821877
31 Dec 2514-802074
30 Sep 253-971966
30 Jun 253-962066
31 Mar 250-952063
31 Dec 2416-772259
30 Sep 2416-572456
30 Jun 2416-592853
31 Mar 2416-582951
31 Dec 230-743150
30 Sep 230-943368
30 Jun 230-993372
31 Mar 230-1093578
31 Dec 220-1213786
30 Sep 220-1013864
30 Jun 220-883352
31 Mar 220-712738
31 Dec 210-761951
30 Sep 210-641147
30 Jun 210-53842
31 Mar 210-47640
31 Dec 200-1349

Quality Earnings: PYXS is currently unprofitable.

Growing Profit Margin: PYXS is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PYXS is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare PYXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PYXS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: PYXS has a negative Return on Equity (-261.4%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/10 21:43
End of Day Share Price 2026/06/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pyxis Oncology, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Bradley CaninoGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.